[{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PBT2","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alterity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Professor Colin Masters","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PBT2","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Alterity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Professor Colin Masters","highestDevelopmentStatusID":"4","companyTruncated":"Alterity Therapeutics \/ Professor Colin Masters"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : PBT2 is a low molecular weight drug candidate, orally bioavailable, crosses the blood-brain barrier, it has demonstrated efficacy in individuals with alzheimer’s disease.

                          Product Name : PBT2

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 14, 2023

                          Lead Product(s) : PBT2

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : Under the license agreement, Alterity grants the entire rights to the AH patent as well as an exclusive worldwide license to develop and commercialize both AH and PBT2 (acyl hydrazone) in Alzheimer’s disease (AD).

                          Product Name : PBT2

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 14, 2023

                          Lead Product(s) : PBT2

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Professor Colin Masters

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : ATH434, is an oral agent which inhibits the aggregation of pathological proteins implicated in neurodegeneration disorders like MSA. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron ba...

                          Product Name : ATH434

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 30, 2023

                          Lead Product(s) : ATH434

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank